Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have entered into a collaboration agreement for the discovery, development and ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

The central image depicts currently used strategies for clinical targeting of TGF-β. Below are methods applicable from preclinical screening to clinical practice, including using humanized mouse ...